Alterity Therapeutics to Webcast New bioMUSE Study Data Today

Alterity Therapeutics, a biotechnology company focused on developing treatments for neurodegenerative diseases, has announced an upcoming investor webcast. This event is scheduled for Thursday, 30 May 2024 in Australia and Wednesday, 29 May 2024 in the United States. During the webcast, the company will share significant findings from its bioMUSE Natural History Study and their implications for the Phase 2 clinical trial of ATH434-202.

Dr. David Stamler, CEO of Alterity Therapeutics, will lead the presentation. He will be accompanied by Dr. Daniel Claassen, a key opinion leader and Professor of Neurology at Vanderbilt University Medical Center. Dr. Claassen, who serves as the Principal Investigator for the bioMUSE study and the Coordinating Investigator for the ATH434-201 Phase 2 clinical trial, will provide expert insights.

The webcast is structured to accommodate participants from both Australia and the United States. Australian participants can join on Thursday, 30 May 2024, at 10:00 a.m. AEST, while U.S. participants can join on Wednesday, 29 May 2024, at 5:00 p.m. Pacific Time or 8:00 p.m. Eastern Time. Registration is mandatory, and participants will receive dial-in details upon registering through the provided link.

During the webcast, investors will have the opportunity to ask questions following the presentation. Additionally, questions can be submitted in advance to Hannah Howlett through email.

Alterity Therapeutics, headquartered in Melbourne, Australia, and San Francisco, California, is at the forefront of developing innovative treatments for neurodegenerative conditions. Their flagship product, ATH434, is currently under evaluation in two Phase 2 clinical trials targeting Multiple System Atrophy. The company’s extensive drug discovery platform aims to develop patentable compounds addressing the root causes of neurological diseases.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!